Votrient pazopanib regulatory update

FDA's Oncologic Drugs Advisory Committee voted 11-2 that the benefit-risk profile of GlaxoSmithKline's Votrient pazopanib supports approval to treat advanced soft tissue sarcoma. Committee members wer...